Hong Kong, 27 March 2026 — China Resources Pharmaceutical Group Limited (stock name: CHINARES PHARMA) announced that its non-wholly-owned subsidiary, CR Pharmaceutical Commercial, has finalised the public issuance of the first tranche of its 2026 corporate bonds in mainland China.

The tranche raised RMB1.80 billion, carries a three-year tenor and bears a fixed coupon of 1.70% per annum. The offering forms part of a broader programme approved by the China Securities Regulatory Commission, allowing CR Pharmaceutical Commercial to issue up to RMB20.00 billion of bonds to qualified domestic investors.

Net proceeds are earmarked for production-related expenditures, including working-capital replenishment, repayment of interest-bearing debt and project investments, in accordance with relevant laws and regulations.

The company reiterated its usual caution for shareholders and potential investors when dealing in its securities.